KPIs & Operating Metrics(New)

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Moderna (MRNA) Acquisitions (2023)

Moderna (MRNA) has disclosed Acquisitions for 1 consecutive years, with $85.0 million as the latest value for Q1 2023.

For Q1 2023, Acquisitions changed N/A year-over-year to $85.0 million; the TTM value through Dec 2023 reached $85.0 million, changed N/A, while the annual FY2023 figure was $85.0 million, N/A changed from the prior year.
Acquisitions hit $85.0 million in Q1 2023 for Moderna.
Across five years, Acquisitions topped out at $85.0 million in Q1 2023 and bottomed at $85.0 million in Q1 2023.